Transparency Market Research discusses the future of the global diabetes injection pens market in its research report. The researchers have analyzed every segment of the global market using a SWOT analysis. This market measurement tool identifies strengths, weaknesses, opportunities, and threats impacting the segments of the global market. The analysts state that diabetes is a result of dysfunctional metabolism that leads to high blood sugar due to inadequate production of insulin or due to its lack of absorption. Diabetes is categorized into juvenile diabetes, type 1, type 2, and gestational diabetes.
View Exclusive Global Strategic Business Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=8806
The type 1 diabetics along with juvenile diabetics require diabetes insulin pens to administer insulin to control blood sugar levels. In cases where type 2 diabetes is not managed well, it often leads to insulin dependency. The high prevalence of type 1 and juvenile diabetes has resulted in the spike in demand of diabetes injection pens in recent years. These pens are also gaining traction due to their ease of portability and convenience in administering the right dosage of insulin. Technological advancements, which have rendered the pens reusable are also providing an impetus to the global market. The popularly selling brands of diabetic injection pens in the global diabetes injection pens market are Apidra SoloStar, SymlinPen 60 & 120, Byetta, Victoza, HumaPen LUXURA HD, Humalog KwikPen, Humulin Pen, Levemir FlexPen, Lantus Solostar, NovoLogMix FlexPen, AutoPen, and NovoPen 3/ NovoPen Junior.
In terms of geography, the global diabetes injection pens market is segmented into Asia Pacific, Europe, North America, the Middle East and Africa, Latin America, and the Rest of the world. The strong presence of big players in North America has kept the region in the forefront of the global market in 2014. The North America diabetes injection pens market is also thriving due to the early onset and detection of diabetes amongst the overall population in the region and sizeable expenditure on the healthcare infrastructure of the region. Analysts predict that Asia Pacific is also likely to be an emerging market of diabetes injection pens in the near future as the governments in the region are vying to fulfill the medical needs of growing number of diabetics.
Some of the key players operating in the global diabetes injection pen market are F. Hoffman-La Roche AG, Medtronic, Novo Nordisk, Becton Dickson and Company, Eli Lilly and Company, and Sanofi S.A. The research report provides a complete overview of the competitive landscape of the global diabetes injection pens market. The report has been carefully collaborated using primary and secondary research methodologies to enable readers to understand the dynamics governing the global market.
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453